The OB-GARDs are anti-obesity devices, within the GARD FAMILY of devices.
Three different devices are planned, with different tubes lengths.
The OB1-GARDTM (the shortest tube) indication is level 1 obesity with a BMI of 30 to 34.9. The end of the OB1-GARDTM reaches the stomach.
The OB2-GARD TM (the middle-size tube) will have tubes reaching through the stomach to the duodenum and will mimic the second most frequent bariatric operation, namely the “sleeve gastrectomy” but without surgery and does not require three-quarters of the stomach to be removed. It will be placed via insertion through the mouth, entailing at most a one-hour procedure. Although sleeve gastrectomy is often associated with reflux, the OB2-GARD will block reflux and help the patient lose weight.
The OB2-GARD TM is indicated for level 2 obesity with a BMI of 35 to 39.9.
The OB3-GARD TM (the longest tube) will have tubes that go through the stomach and through the duodenum to the jejunum, mimicking the gastric by-pass operation (the most invasive operation) and provides a safer, non-surgical replacement. The length of the OB3-GARD can be calibrated to the severity of the obesity. Moreover, the longer the tube, the greater the expected weight loss.
The OB3-GARD TM is indicated for morbid obesity, that is BMIs of more than 40.
Treatment with OB-GARDs will be accompanied by diet counseling.
Clinical trials are planned for 2022-2023
EXPECTED SALES DATE – 2024 in Europe, 2025 in the USA.